Skip to main content

Advertisement

SpringerLink
Log in

Estrogens and selective estrogen receptor modulators in acromegaly

  • Mini Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Despite recent advances in acromegaly treatment by surgery, drugs, and radiotherapy, hormonal control is still not achieved by some patients. The impairment of IGF-1 generation by estrogens in growth hormone deficient patients is well known. Patients on oral estrogens need higher growth hormone doses in order to achieve normal IGF-1 values. In the past, estrogens were one of the first drugs used to treat acromegaly. Nevertheless, due to the high doses used and the obvious side effects in male patients, this strategy was sidelined with the development of more specific drugs, as somatostatin receptor ligands and dopamine agonists. In the last 15 years, the antagonist of growth hormone receptor became available, making possible IGF-1 control of the majority of patients on this particular drug. However, due to its high cost, pegvisomant is still not available in many centers around the world. In this setting, the effect of estrogens and also of selective estrogen receptor modulators on IGF-1 control was reviewed, and proved to be an ancillary tool in the management of acromegaly. This review describes data concerning their efficacy and place in the treatment algorithm of acromegaly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. T.A. Howlett, D. Willis, G. Walker, J.A. Wass, P.J. Trainer, U.K.A.R.S. Group, Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin. Endocrinol. (Oxf) 79(5), 689–699 (2013). doi:10.1111/cen.12207

    CAS  Google Scholar 

  2. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). doi:jc.2008-2421 [pii] 10.1210/jc.2008-2421

    Article  CAS  PubMed  Google Scholar 

  3. P. Burman, A.G. Johansson, A. Siegbahn, B. Vessby, F.A. Karlsson, Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J. Clin. Endocrinol. Metab. 82(2), 550–555 (1997). doi:10.1210/jcem.82.2.3776

    CAS  PubMed  Google Scholar 

  4. J.O. Jorgensen, J.J. Christensen, M. Krag, S. Fisker, P. Ovesen, J.S. Christiansen, Serum insulin-like growth factor I levels in growth hormone-deficient adults: influence of sex steroids. Horm. Res 62(Suppl 1), 73–76 (2004). doi:10.1159/000080762

    CAS  PubMed  Google Scholar 

  5. J.M. Janssen, R. Bland, M. Hewison, M.W. Coughtrie, S. Sharp, J. Arts, H.A. Pols, J.P. van Leeuwen, Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J. Cell Biochem. 75(3), 528–537 (1999)

    Article  CAS  PubMed  Google Scholar 

  6. A.J. Brooks, J.W. Wooh, K.A. Tunny, M.J. Waters, Growth hormone receptor; mechanism of action. Int. J. Biochem. Cell Biol. 40(10), 1984–1989 (2008). doi:10.1016/j.biocel.2007.07.008

    Article  CAS  PubMed  Google Scholar 

  7. D.J. Waxman, C. O’Connor, Growth hormone regulation of sex-dependent liver gene expression. Mol. Endocrinol. 20(11), 2613–2629 (2006). doi:10.1210/me.2006-0007

    Article  CAS  PubMed  Google Scholar 

  8. O.M. Vidal, R. Merino, E. Rico-Bautista, L. Fernandez-Perez, D.J. Chia, J. Woelfle, M. Ono, B. Lenhard, G. Norstedt, P. Rotwein, A. Flores-Morales, In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol. Endocrinol. 21(1), 293–311 (2007). doi:10.1210/me.2006-0096

    Article  CAS  PubMed  Google Scholar 

  9. B. Dawson-Hughes, D. Stern, J. Goldman, S. Reichlin, Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J. Clin. Endocrinol. Metab. 63(2), 424–432 (1986). doi:10.1210/jcem-63-2-424

    Article  CAS  PubMed  Google Scholar 

  10. A.G. Nugent, K.C. Leung, D. Sullivan, A.T. Reutens, K.K. Ho, Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin. Endocrinol. (Oxf) 59(6), 690–698 (2003). doi:10.1046/j.1365-2265.2003.01907.x

    Article  CAS  Google Scholar 

  11. J. Gibney, G. Johannsson, K.C. Leung, K.K. Ho, Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J. Clin. Endocrinol. Metab. 90(7), 3897–3903 (2005). doi:10.1210/jc.2005-0173

    Article  CAS  PubMed  Google Scholar 

  12. J.J. Kelly, I.A. Rajkovic, A.J. O’Sullivan, C. Sernia, K.K. Ho, Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin. Endocrinol. (Oxf) 39(5), 561–567 (1993)

    Article  CAS  Google Scholar 

  13. D.M. Cook, W.H. Ludlam, M.B. Cook, Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J. Clin. Endocrinol. Metab. 84(11), 3956–3960 (1999). doi:10.1210/jcem.84.11.6113

    CAS  PubMed  Google Scholar 

  14. A.J. Weissberger, K.K. Ho, L. Lazarus, Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72(2), 374–381 (1991). doi:10.1210/jcem-72-2-374

    Article  CAS  PubMed  Google Scholar 

  15. T. Wolthers, D.M. Hoffman, A.G. Nugent, M.W. Duncan, M. Umpleby, K.K. Ho, Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am. J. Physiol. Endocrinol. Metab. 281(6), E1191–E1196 (2001)

    CAS  PubMed  Google Scholar 

  16. K.E. Friend, M.L. Hartman, S.S. Pezzoli, J.L. Clasey, M.O. Thorner, Both oral and transdermal estrogen increase growth hormone release in postmenopausal women—a clinical research center study. J. Clin. Endocrinol. Metab. 81(6), 2250–2256 (1996). doi:10.1210/jcem.81.6.8964860

    CAS  PubMed  Google Scholar 

  17. K.K. Ho, A.J. Weissberger, Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J. Bone. Miner. Res. 7(7), 821–827 (1992). doi:10.1002/jbmr.5650070711

    Article  CAS  PubMed  Google Scholar 

  18. J. Slowinska-Srzednicka, S. Zgliczynski, W. Jeske, U. Stopinska-Gluszak, M. Srzednicki, A. Brzezinska, W. Zgliczynski, Z. Sadowski, Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J. Endocrinol. Invest. 15(7), 533–538 (1992)

    Article  CAS  PubMed  Google Scholar 

  19. R.B. Colletti, J.D. Roberts, J.T. Devlin, K.C. Copeland, Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer. Res. 49(7), 1882–1884 (1989)

    CAS  PubMed  Google Scholar 

  20. E.A. Lien, D.C. Johannessen, A. Aakvaag, P.E. Lonning, Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J. Steroid. Biochem. Mol. Biol. 41(3-8), 541–543 (1992)

    Article  CAS  PubMed  Google Scholar 

  21. M. Pollak, J. Costantino, C. Polychronakos, S.A. Blauer, H. Guyda, C. Redmond, B. Fisher, R. Margolese, Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst. 82(21), 1693–1697 (1990)

    Article  CAS  PubMed  Google Scholar 

  22. S.I. Helle, J.M. Holly, M. Tally, K. Hall, J. Vander Stappen, P.E. Lonning, Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int. J. Cancer 69(4), 335–339 (1996). doi:10.1002/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4

    Article  CAS  PubMed  Google Scholar 

  23. A. Decensi, B. Bonanni, A. Guerrieri-Gonzaga, S. Gandini, C. Robertson, H. Johansson, R. Travaglini, M.T. Sandri, A. Tessadrelli, G. Farante, F. Salinaro, D. Bettega, A. Barreca, P. Boyle, A. Costa, U. Veronesi, Biologic activity of tamoxifen at low doses in healthy women. J. Natl. Cancer Inst. 90(19), 1461–1467 (1998)

    Article  CAS  PubMed  Google Scholar 

  24. M. Mandala, C. Moro, G. Ferretti, M.G. Calabro, F. Nole, A. Rocca, E. Munzone, A. Castro, G. Curigliano, Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Anticancer Res. 21(1B), 585–588 (2001)

    CAS  PubMed  Google Scholar 

  25. V. Birzniece, A. Sata, S. Sutanto, K.K. Ho, Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J. Clin. Endocrinol. Metab. 95(12), 5443–5448 (2010). doi:10.1210/jc.2010-1477

    Article  CAS  PubMed  Google Scholar 

  26. V. Birzniece, K.K. Ho, Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes. Eur. J. Endocrinol. 173(4), 479–487 (2015). doi:10.1530/EJE-15-0426

    Article  CAS  PubMed  Google Scholar 

  27. V. Birzniece, S. Sutanto, K.K. Ho, Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J. Clin. Endocrinol. Metab. 97(4), E521–527 (2012). doi:10.1210/jc.2011-3347

    Article  CAS  PubMed  Google Scholar 

  28. D.B. Muchmore, Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5(5), 388–392 (2000)

    Article  CAS  PubMed  Google Scholar 

  29. A.M. Oleksik, T. Duong, N. Pliester, G. Asma, C. Popp-Snijders, P. Lips, Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J. Clin. Endocrinol. Metab. 86(6), 2763–2768 (2001). doi:10.1210/jcem.86.6.7549

    Article  CAS  PubMed  Google Scholar 

  30. E.J. Duschek, G.W. de Valk-de Roo, L.J. Gooren, C. Netelenbos, Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. Fertil. Steril. 82(2), 384–390 (2004). doi:10.1016/j.fertnstert.2004.01.033

    Article  CAS  PubMed  Google Scholar 

  31. A. Cakmak, C. Posaci, E. Dogan, S. Caliskan, S. Guclu, S. Altunyurt, Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. Am. J. Obstet. Gynecol. 193(2), 347–351 (2005). doi:10.1016/j.ajog.2005.01.023

    Article  CAS  PubMed  Google Scholar 

  32. A. Lasco, A. Gaudio, E. Morini, N. Morabito, C. Nicita-Mauro, A. Catalano, G. Denuzzo, C. Sansotta, A. Xourafa, I. Macri, N. Frisina, Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. Menopause 13(5), 787–792 (2006). doi:10.1097/01.gme.0000233493.20712.ad

    Article  PubMed  Google Scholar 

  33. R. Torrisi, L. Baglietto, H. Johansson, G. Veronesi, B. Bonanni, A. Guerrieri-Gonzaga, B. Ballardini, A. Decensi, Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br. J. Cancer 85(12), 1838–1841 (2001). doi:10.1054/bjoc.2001.2191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. B.B. da Silva, D.S. Moita, C.G. Pires, E.C. Sousa-Junior, A.R. dos Santos, P.V. Lopes-Costa, Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene. Int. Semin. Surg. Oncol. 4, 18 (2007). doi:10.1186/1477-7800-4-18

    Article  PubMed  PubMed Central  Google Scholar 

  35. V. Birzniece, U. Meinhardt, J. Gibney, G. Johannsson, R.C. Baxter, M.J. Seibel, K.K. Ho, Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women. J. Clin. Endocrinol. Metab. 95(5), 2099–2106 (2010). doi:10.1210/jc.2009-2743

    Article  CAS  PubMed  Google Scholar 

  36. E.J. Duschek, L.J. Gooren, C. Netelenbos, Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas 51(3), 286–293 (2005). doi:10.1016/j.maturitas.2004.08.011

    Article  CAS  PubMed  Google Scholar 

  37. J. Eng-Wong, S.D. Hursting, D. Venzon, S.N. Perkins, J.A. Zujewski, Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol. Biomarkers Prev. 12(12), 1468–1473 (2003)

    CAS  PubMed  Google Scholar 

  38. V. Birzniece, N.E. Magnusson, K.K. Ho, J. Frystyk, Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women. Eur. J. Endocrinol. 170(3), 375–383 (2014). doi:10.1530/EJE-13-0835

    Article  CAS  PubMed  Google Scholar 

  39. Practice Committee of the American Society for Reproductive, M., Use of clomiphene citrate in infertile women: a committee opinion. Fertil. Steril. 100(2), 341–348 (2013). doi:10.1016/j.fertnstert.2013.05.033

    Article  Google Scholar 

  40. L.W. Roth, A.R. Ryan, R.B. Meacham, Clomiphene citrate in the management of male infertility. Semin. Reprod. Med 31(4), 245–250 (2013). doi:10.1055/s-0033-1345271

    Article  CAS  PubMed  Google Scholar 

  41. T.L. Butzow, L.M. Kettel, S.S. Yen, Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome. Fertil. Steril. 63(6), 1200–1203 (1995)

    Article  CAS  PubMed  Google Scholar 

  42. V. de Leo, A. la Marca, G. Morgante, L. Ciotta, L. Mencaglia, A. Cianci, F. Petraglia, Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome. Hum. Reprod. 15(11), 2302–2305 (2000)

    Article  PubMed  Google Scholar 

  43. T.M. Fiad, T.P. Smith, S.K. Cunningham, T.J. McKenna, Decline in insulin-like growth factor I levels after clomiphene citrate does not correct hyperandrogenemia in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83(7), 2394–2398 (1998). doi:10.1210/jcem.83.7.4921

    Article  CAS  PubMed  Google Scholar 

  44. A.A. Rouzi, M.S. Ardawi, A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil. Steril. 85(2), 428–435 (2006). doi:10.1016/j.fertnstert.2005.07.1312

    Article  CAS  PubMed  Google Scholar 

  45. R.S. Morris, V.C. Karande, A. Dudkiewicz, J.L. Morris, N. Gleicher, Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Fertil. Steril. 71(3), 452–456 (1999)

    Article  CAS  PubMed  Google Scholar 

  46. H. Huynh, M. Pollak, Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem. Biophys. Res. Commun. 203(1), 253–259 (1994). doi:10.1006/bbrc.1994.2175

    Article  CAS  PubMed  Google Scholar 

  47. L. Canobbio, D. Cannata, L. Miglietta, F. Boccardo, Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res. 15(6B), 2687–2690 (1995)

    CAS  PubMed  Google Scholar 

  48. J.N. Ingle, V.J. Suman, C.G. Kardinal, J.E. Krook, J.A. Mailliard, M.H. Veeder, C.L. Loprinzi, R.J. Dalton, L.C. Hartmann, C.A. Conover, M.N. Pollak, A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85(6), 1284–1292 (1999)

    Article  CAS  PubMed  Google Scholar 

  49. M.N. Pollak, H.T. Huynh, S.P. Lefebvre, Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res. Treat. 22(1), 91–100 (1992)

    Article  CAS  PubMed  Google Scholar 

  50. H.M. Domene, G. Marin, J. Sztein, Y.M. Yu, J. Baron, F.G. Cassorla, Estradiol inhibits growth hormone receptor gene expression in rabbit liver. Mol. Cell Endocrinol. 103(1-2), 81–87 (1994). doi:0303-7207(94)90072-8 [pii]

    Article  CAS  PubMed  Google Scholar 

  51. K.K. Ho, E. Valiontis, M.J. Waters, I.A. Rajkovic, Regulation of growth hormone binding protein in man: comparison of gel chromatography and immunoprecipitation methods. J. Clin. Endocrinol. Metab. 76(2), 302–308 (1993). doi:10.1210/jcem.76.2.8432772

    CAS  PubMed  Google Scholar 

  52. H.T. Huynh, E. Tetenes, L. Wallace, M. Pollak, In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 53(8), 1727–1730 (1993)

    CAS  PubMed  Google Scholar 

  53. K.C. Leung, G. Johannsson, G.M. Leong, K.K. Ho, Estrogen regulation of growth hormone action. Endocr. Rev. 25(5), 693–721 (2004). doi:10.1210/er.2003-0035

    Article  CAS  PubMed  Google Scholar 

  54. G.M. Leong, S. Moverare, J. Brce, N. Doyle, K. Sjogren, K. Dahlman-Wright, J.A. Gustafsson, K.K. Ho, C. Ohlsson, K.C. Leung, Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology 145(12), 5525–5531 (2004). doi:10.1210/en.2004-0061

    Article  CAS  PubMed  Google Scholar 

  55. K.C. Leung, N. Doyle, M. Ballesteros, K. Sjogren, C.K. Watts, T.H. Low, G.M. Leong, R.J. Ross, K.K. Ho, Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc. Natl. Acad. Sci. U S A 100(3), 1016–1021 (2003). doi:10.1073/pnas.0337600100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. L. Fernandez, A. Flores-Morales, O. Lahuna, D. Sliva, G. Norstedt, L.A. Haldosen, A. Mode, J.A. Gustafsson, Desensitization of the growth hormone-induced Janus kinase 2 (Jak 2)/signal transducer and activator of transcription 5 (Stat5)-signaling pathway requires protein synthesis and phospholipase C. Endocrinology 139(4), 1815–1824 (1998). doi:10.1210/endo.139.4.5931

    CAS  PubMed  Google Scholar 

  57. B. Mozzanega, G.L. Babbo, L. Salmaso, R. De Toni, A. Schiavo, R. Mioni, S.V. de Kreutzenberg, Oral 17beta-estradiol and sequential progesterone in menopause: effects on insulin-like growth factors and their binding proteins. Gynecol. Endocrinol. 23(1), 50–57 (2007)

    Article  CAS  PubMed  Google Scholar 

  58. E. Wiedemann, E. Schwartz, Suppression of growth hormone-dependent human serum sulfation factor by estrogen. J. Clin. Endocrinol. Metab. 34(1), 51–58 (1972)

    Article  PubMed  Google Scholar 

  59. D.R. Clemmons, L.E. Underwood, E.C. Ridgway, B. Kliman, R.N. Kjellberg, J.J. Van Wyk, Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am. J. Med. 69(4), 571–575 (1980). doi:0002-9343(80)90470-2 [pii]

    Article  CAS  PubMed  Google Scholar 

  60. S. Almqvist, D. Ikkos, R. Luft, Studies on sulfation factor (SF) activity of human serum. The effects of oestrogen and x-ray therapy on serum SF activity in acromegaly. Acta Endocrinol. (Copenh) 37, 138–147 (1961)

    CAS  Google Scholar 

  61. S. Vallette, O. Serri, Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13(4), 311–314 (2010). doi:10.1007/s11102-010-0236-5

    Article  CAS  PubMed  Google Scholar 

  62. I. Shimon, A. Barkan, Estrogen treatment for acromegaly. Pituitary 15(4), 601–607 (2012). doi:10.1007/s11102-012-0426-4

    Article  CAS  PubMed  Google Scholar 

  63. R. Cozzi, M. Barausse, S. Lodrini, G. Lasio, R. Attanasio, Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J. Endocrinol. Invest. 26(4), 347–352 (2003). doi:10.1007/BF03345183

    Article  CAS  PubMed  Google Scholar 

  64. R. Cozzi, R. Attanasio, G. Oppizzi, P. Orlandi, A. Giustina, S. Lodrini, N. Da Re, D. Dallabonzana: Effects of tamoxifen on GH and IGF-I levels in acromegaly. J. Endocrinol. Invest. 20(8), 445–451 (1997)

    Article  CAS  PubMed  Google Scholar 

  65. J.C. Maiza, S. Castillo-Ros, M. Matta, A. Bennet, P. Caron, Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide. Pituitary 15(Suppl 1), S23–S27 (2012). doi:10.1007/s11102-010-0287-7

    Article  PubMed  Google Scholar 

  66. I. Balili, A. Barkan, Tamoxifen as a therapeutic agent in acromegaly. Pituitary 17(6), 500–504 (2014). doi:10.1007/s11102-013-0534-9

    Article  CAS  PubMed  Google Scholar 

  67. R. Attanasio, M. Barausse, R. Cozzi, Raloxifene lowers IGF-I levels in acromegalic women. Eur. J. Endocrinol. 148(4), 443–448 (2003)

    Article  CAS  PubMed  Google Scholar 

  68. E.V. Dimaraki, K.V. Symons, A.L. Barkan, Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur. J. Endocrinol. 150(4), 481–487 (2004)

    Article  CAS  PubMed  Google Scholar 

  69. F.H. Duarte, R.S. Jallad, M.D. Bronstein, Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J. Clin. Endocrinol. Metab. 100(5), 1863–1869 (2015). doi:10.1210/jc.2014-3913

    Article  CAS  PubMed  Google Scholar 

  70. J.C. Stone, J. Clark, R. Cuneo, A.W. Russell, S.A. Doi, Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies. Pituitary 17(3), 284–295 (2014). doi:10.1007/s11102-013-0504-2

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, Brazil

    Felipe H. Duarte, Raquel S. Jallad & Marcello D. Bronstein

  2. Endocrinology Service, AC Camargo Cancer Center, São Paulo, Brazil

    Felipe H. Duarte

Authors
  1. Felipe H. Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquel S. Jallad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcello D. Bronstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello D. Bronstein.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Disclosure statement

MDB: Consultant and member of Steering Committees: Chiasma, Ipsen, Novartis. Speaker: Ipsen, Novartis, Pfizer. Principal investigator of Clinical Trials: Ipsen, Novartis, Pfizer; RSJ: Sub-investigator of Clinical Trials (Novastis, Ipsen); FHD: Sub-investigator of Clinical Trial (Novartis)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duarte, F.H., Jallad, R.S. & Bronstein, M.D. Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine 54, 306–314 (2016). https://doi.org/10.1007/s12020-016-1118-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-1118-z

Keywords

Search

Navigation